Researchers Outline Agenda to Elucidate Caregivers’ Experience

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 9
Volume 10
Issue 9

EAST LANSING, Mich-Although much of cancer care now takes place in the outpatient and home setting, the oncology care system has not fully incorporated "family care" for patients at home. While this shift has translated into increased family involvement in day-to-day care, there are few documented, effective strategies to guide family members caring for patients with advanced cancer.

EAST LANSING, Mich—Although much of cancer care now takes place in the outpatient and home setting, the oncology care system has not fully incorporated "family care" for patients at home. While this shift has translated into increased family involvement in day-to-day care, there are few documented, effective strategies to guide family members caring for patients with advanced cancer.

The cover article of the July/August 2001 issue of CA—A Cancer Journal for Clinicians calls for a research agenda to more fully elucidate the cancer caregiver’s experience throughout the illness and treatment trajectory, and identify the means to effecting positive outcomes for people with cancer, their family caregiver, and the health care system.

"Caregivers’ well being must be our concern," say authors Barbara Given, RN, PhD; Charles Given, PhD; and Sharon Kozachik, RN, MSN, of Michigan State University. They suggest four areas for future research: symptom management strategies, patient-caregiver communication, defining patient outcomes, and cost effectiveness. 

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content